A hipertensão arterial é definida como doença crônica não transmissível em que ocorre elevação sustentada da pressão arterial, cujo benefício do tratamento, seja medicamen - toso ou não, supera os riscos. Por se tratar de condição frequentemente assintomática, a evolução pode ocasionar alteração estrutural e funcional de órgãos-alvo importantes como coração, cérebro, rins e vasos sanguíneos e está associada a fatores de risco metabólicos como dislipidemia, obesidade abdominal, intolerância à glicose e diabetes melito. O tratamento visa a redução da morbidade e mortalidade cardiovascular e pode ser medicamentoso, que abrange sete classes principais de fármacos, ou não medicamentoso, que compreende principalmente mudança do estilo de vida, sendo esta a primeira proposta terapêutica em casos leves. O sucesso para o controle pressórico envolve a adesão ao tratamento não medicamentoso e medicamentoso, sendo este o principal foco de atuação do farmacêutico clínico. A presente pesquisa trata-se de uma revisão narrativa feita através do levantamento bibliográfico de artigos científicos nas bases de dados SCIELO, PUBMED e Google Acadêmico, em língua portuguesa, considerando os indivíduos hipertensos aqueles com PAS ≥ 140 mmHg e/ou PAD ≥ 90 mmHg. O papel do farmacêutico clínico é estar inserido no cuidado do paciente, participando ativamente da terapia medicamentosa, da promoção e/ou recuperação da saúde, exercendo suas atividades com autonomia para a tomada de decisão baseada nos princípios éticos da profissão, abrangendo tanto pacientes ambulatoriais quanto os internados. Esse profissional atua na avaliação da prescrição médica, na conciliação medicamentosa, na avaliação da adesão farmacoterapêutica, traçando um plano farmacoterapêutico e promovendo a educação em saúde, tanto do paciente quanto do cuidador.

≥18 yr old admitted for at least 24 hr after non-cardiac surgery. The primary outcome was relative risk of delirium in the ICU between patients on chronic gabapentin or pregabalin and patients who did not take the listed medication. The delirium event was determined as at least one positive CAM-ICU assessment. Our primary analysis was conducted by fitting a logistic regression model with delirium event as a binary outcome. The results of the comparison were adjusted directly in the model by baseline and perioperative confounding variables. Results: Between January 2013 and June 2014, there were 1,313 SICU patients who satisfied inclusion and had complete data on the confounding variables with 326 (25%) of them on GABA medications and 987 (75%) patients not on GABA medications. After controlling for potential confounding variables, use of GABA medications prior to admission compared with no use was not significantly associated with an increase in delirium (50% vs. 47%). The odds ratio of experiencing delirium for patients on chronic GABA medications compared to patients not on chronic GABA medications was 1.2 (95% CI, 0.9, 1.7, p=0.3). Conclusions: The chronic use of gabapentin or pregabalin prior to SICU admission compared with no use was not associated with an increase in delirium in the ICU when the drugs are abruptly held.Learning Objectives: Objectives: 1) To test the hypothesis that intraventricular extension of spontaneous intracerebral hemorrhage in the absence of hydrocephalus is not associated with increased mortality or severe disability. 2) To modify current ICH scoring system for a possible better prognostication. 3) To assess whether shorter time interval from development of hydrocephalus to ventriculostomy is correlated with the functional outcome or not. Methods: Methods: A retrospective consecutive cohort study of patients with primary spontaneous intracerebral hemorrhage (ICH) who were admitted to a single institution was performed. Multivariate logistic regression analysis was used to assess correlation of each variable with functional outcome measured as modified Rankin Scale (mRS). A modified ICH scoring system was proposed based on the information obtained from the first part. For those patients who underwent ventriculostomy, the time interval from development of hydrocephalus to ventriculostomy was assessed in regards to mRS. Results: Results: A total number of 164 patients met our inclusion criteria and entered the study. Only three variables met statistical significance for their association with increased mortality or severe disability (mRS of 6 or 5). These variables including hydrocephalus (p=0.002); hematoma volume (p=0.003) and initial Glasgow Coma Scale (p=0.017) were considered in our modified ICH scoring system. Conclusions: Conclusion: The presence of intraventricular extension of ICH in the absence of hydrocephalus does not increase mortality or severe disability. The shorter time interval from development of hydrocephalus to ventriculostomy may not improve functional outcome. Ou...